



2025 YEAR-END

INTERVIEW

**A Conversation
with Dr. Eagle**



inquiry@asymchem.com

www.asymchem.com


2025 YEAR-END INTERVIEW



467 AUTHORIZED
PATENTS IN TOTAL

180 in Flow
Technology

151 in Synthetic
Biology



Dr. Eagle,

what's the best compliment a partner gave you in 2025? Was it something like, "This makes everything easier for us"? What was behind that?

Asymchem accelerated technology advancement and expanded its global patent portfolio. Key progress includes:

INTEGRATED FLOW TECHNOLOGY

Deploying an "**R&D + Equipment**" approach to advance **flow technology** and enable external technology transfer, supporting transformation in fine chemical manufacturing.

END-TO-END SYNTHETIC BIOLOGY WORKFLOW

Operating a fully automated workflow from enzyme design to product development—powered by proprietary platforms in **DNA synthesis, sequencing, continuous enzymatic synthesis, and recombinant technologies.**

PRODUCT DEVELOPMENT IN SYNTHETIC BIOLOGY

Entering **new markets** (e.g., cosmetic/personal care) by leveraging advancements in the production of **salidroside, sclareol, and resveratrol.**

PUBLISHED RESEARCH & INDUSTRY RECOGNITION

Key innovations such as the **enzymatic synthesis of eflornithine** have been published in leading scientific journals, receiving broad industry recognition.



2025 YEAR-END INTERVIEW



Dr. Eagle,

what new “key” did your team forge this year that opened the most exciting new doors?

Asymchem strengthened its capabilities in key therapeutic areas, supporting multiple potential blockbuster candidates globally through:

ADVANCED TIDES TECHNOLOGIES

Biosynthesis, enzymatic ligation, green liquid-phase peptide synthesis (LPPS), fluidized bed oligonucleotide synthesis, stirred bed solid-phase oligonucleotide synthesis, on-column ammonolysis, recombinant synthesis, and TFA cleavage, enable scalable production of complex peptides and oligonucleotides.

INTEGRATED FORMULATION & DRUG DELIVERY

Cutting-edged platforms support emerging modalities including **PROTACs**, **molecular glues**, and advanced oligonucleotide dosage forms.

ESTABLISHED BIOLOGICS MANUFACTURING & CORE PLATFORMS

Global market launches are empowered by robust commercial manufacturing and proprietary platforms including **Amigo CHO™** and **ADC Toolbox**.

2025 YEAR-END INTERVIEW



Dr. Eagle,

what gave you and the team the most quiet confidence that Sandwich wasn't just a new address, but a truly capable part of the global network?

Asymchem's Sandwich site completed its first year with strong delivery, quality performance, and capability growth.

OPERATIONAL & PROJECT DELIVERY

- Completed **10 projects**, with 8 active projects ongoing
- Delivered **3 manufacturing campaigns**, each achieving higher-than-expected yields

QUALITY & REGULATORY MILESTONES

- Passed a UK **MHRA GMP audit** with no critical findings
- Passed **PSCI EHS audit** pending validation of findings
- Passed the pre-assessment for **ISO 14001** accreditation

INDUSTRY ENGAGEMENT & OUTREACH

- Hosted the first Asymchem European symposium at the Shard, London
- Actively participated in leading international industry conferences to strengthen visibility and network

TECHNOLOGY & INFRASTRUCTURE DEVELOPMENT

- Enhanced technical capabilities in **flow chemistry**, **biocatalysis screening**, and **photo-/electrochemistry**
- **Expanded HTE lab**
- **GMP lab** and **pilot-scale flow hydrogenation unit** in development



2025 YEAR-END INTERVIEW



Dr. Eagle,

if your team's work is like building bridges for partners, what's one new "bridge" you built this year that you're most excited about?

Driven by global market demand, Asymchem actively expanded its strategic capacity across key business areas in 2025:

DEDICATED PEPTIDE & HPAPI CAPABILITIES

- Solid-phase peptide synthesis (SPPS) capacity projected to reach **44,000 liters**
- New **OEB5** manufacturing and R&D facilities launched for high-potency drugs and novel conjugates

SUFFICIENT FORMULATION & SOLID DOSAGE CAPACITY

- Annual prefilled syringe capacity scaled to **45 million units**
- New **β -lactam** and **cartridge** facilities now operational

BIOTHERAPEUTICS NETWORK SYNERGY

AsymBio's Fengxian, Shanghai Jinshan, and Zhangjiang sites constitute an integrated, one-stop platform for conjugated drug R&D and production



2025 YEAR-END INTERVIEW



Dr. Eagle,

was there a specific time in 2025 when a partner trusted you with something truly unexpected or fragile, and it paid off?



Continuing our track record, we supported multiple new drug launches in 2025. The examples below offer a glimpse into our contributions, selected from the many under confidentiality.

MAZDUTIDE

the world's first GCG/GLP-1 dual-receptor agonist for weight management

UNAFRA (VIVOZON)

the world's first non-opioid, non-NSAIDS analgesic, simultaneously inhibiting Glycine Transporter Type 2 (GlyT2) and Serotonin Receptor 2a (5HT2a)

DS+DP ONE STOP SOLUTION CASES

- Taltrectinib Adipate Capsules
- Luvometinib
- Glecirasib Citrate Tablets
- Bireociclib



2025 YEAR-END INTERVIEW

ESG

SBTi

Dr. Eagle,

let's skip the formal reports for a second. What's the one thing from last year that made you and the team genuinely proud—the story you'd tell over a coffee?

Asymchem has consistently created shared value for society, the industry, customers, and employees through active collaboration with diverse stakeholders.

KEY SOCIAL & INDUSTRY INITIATIVES

- Continuation of the “Xin (Heart of Hope)” charitable program, **funding life-saving surgery for children with congenital heart disease.**
- Implementation of disability support projects in Tianjin and Jilin.
- Hosting of the Pharmaceutical CDMO ESG Practice Forum, fostering critical dialogue on sustainable development within the sector.
- Organization of a **litter-picking volunteering activity** by the **Sandwich Pilot Plant and QA teams** for local environmental benefit.
- Award of the **Silver** level in the Better Stands Programme at **CPHI Frankfurt 2025.**

ENVIRONMENTAL ACHIEVEMENT

Asymchem's Jilin and Tianjin sites successfully obtained validation from **the Science Based Targets initiative (SBTi)**, underscoring our commitment to science-driven climate goals.

2025 YEAR-END INTERVIEW



inquiry@asymchem.com
www.asymchem.com

Dr. Eagle,

is there a message you would like
to share as we look ahead?



Looking ahead to 2026, Asymchem remains committed to accelerating the next wave of innovations and creating sustainable value for our partners, the industry, and society.

We look forward to sharing this exciting journey ahead.